SUPV vs. HRMY
SUPV (Grupo Supervielle S.A.) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. SUPV operates in Banks - Regional (Financial Services), while HRMY operates in Biotechnology (Healthcare). Over the past 5 years, SUPV returned 38.77%/yr vs 1.50%/yr for HRMY. At a 0.14 correlation, their price movements are largely independent.
Performance
SUPV vs. HRMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SUPV achieves a -6.94% return, which is significantly higher than HRMY's -7.91% return.
SUPV
- 1D
- 1.01%
- 1M
- 39.42%
- YTD
- -6.94%
- 6M
- -0.36%
- 1Y
- -3.17%
- 3Y*
- 63.15%
- 5Y*
- 38.77%
- 10Y*
- 0.23%
HRMY
- 1D
- -2.10%
- 1M
- 12.03%
- YTD
- -7.91%
- 6M
- -14.93%
- 1Y
- 4.52%
- 3Y*
- -1.66%
- 5Y*
- 1.50%
- 10Y*
- —
SUPV vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
SUPV Grupo Supervielle S.A. | -6.94% | -20.75% | 281.41% | 87.96% | 11.80% | -6.59% | -16.54% |
HRMY Harmony Biosciences Holdings, Inc. | -7.91% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -9.60% |
Correlation
The correlation between SUPV and HRMY is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Aug 19, 2020 | 0.14 |
Fundamentals
SUPV:
$869.13M
HRMY:
$2.03B
SUPV:
-ARS 72.13
HRMY:
$2.48
SUPV:
1.31
HRMY:
2.25
SUPV:
1.14
HRMY:
2.22
SUPV:
ARS 1.02T
HRMY:
$899.11M
SUPV:
ARS 425.09B
HRMY:
$688.25M
SUPV:
-ARS 9.21B
HRMY:
$221.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SUPV vs. HRMY — Risk / Return Rank
SUPV
HRMY
SUPV vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Grupo Supervielle S.A. (SUPV) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SUPV | HRMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.18 | ||
| Sortino ratioReturn per unit of downside risk | +0.24 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.06 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | -0.15 | 0.10 | -0.25 |
| Martin ratioReturn relative to average drawdown | -0.32 | 0.18 | -0.50 |
Loading charts...
Drawdowns
SUPV vs. HRMY - Drawdown Comparison
The maximum SUPV drawdown since its inception was -95.98%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for SUPV and HRMY.
Loading charts...
Drawdown Indicators
| SUPV | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.98% | -68.48% | -27.50% |
Max Drawdown (1Y)Largest decline over 1 year | -59.91% | -34.49% | -25.42% |
Max Drawdown (3Y)Largest decline over 3 years | -75.20% | -50.81% | -24.39% |
Max Drawdown (5Y)Largest decline over 5 years | -75.20% | -68.48% | -6.72% |
Max Drawdown (10Y)Largest decline over 10 years | -95.98% | — | — |
Current DrawdownCurrent decline from peak | -63.26% | -43.42% | -19.84% |
Average DrawdownAverage peak-to-trough decline | -66.96% | -35.27% | -31.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.53% | 18.73% | +9.80% |
Volatility
SUPV vs. HRMY - Volatility Comparison
Grupo Supervielle S.A. (SUPV) has a higher volatility of 23.01% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 11.05%. This indicates that SUPV's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SUPV | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.01% | 11.05% | +11.96% |
Volatility (6M)Calculated over the trailing 6-month period | 47.05% | 30.44% | +16.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 95.72% | 42.03% | +53.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.42% | 50.13% | +21.29% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.39% | 52.45% | +19.94% |
Dividends
SUPV vs. HRMY - Dividend Comparison
Neither SUPV nor HRMY has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
HRMY Harmony Biosciences Holdings, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SUPV Grupo Supervielle S.A. | 0.00% | 1.71% | 1.12% | 0.00% | 0.71% | 1.36% | 1.79% | 2.03% | 1.32% | 0.30% |
Financials
SUPV vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between Grupo Supervielle S.A. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SUPV vs. HRMY - Profitability Comparison
SUPV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported a gross profit of 169.00M and revenue of 387.59M. Therefore, the gross margin over that period was 43.6%.
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.
SUPV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported an operating income of -15.76M and revenue of 387.59M, resulting in an operating margin of -4.1%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.
SUPV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported a net income of -12.03M and revenue of 387.59M, resulting in a net margin of -3.1%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.
Frequently Asked Questions
SUPV and HRMY have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SUPV has higher volatility (23.01%) compared to HRMY (11.05%). In terms of maximum drawdown, SUPV dropped -95.98% vs HRMY's -68.48%.
HRMY currently has the higher Sharpe Ratio (0.08 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SUPV and HRMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer